Vireo Growth Inc. (VREOF) stock
VREOFOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 11/30
$9.01+0.01 (+0.11%)
Close on Oct 19, 2026Market cap $443.48MP/E –Yield –
Vireo Growth r&d expenses
Research and development expenses are spending on new products and technology.
No r&d expenses figures for Vireo Growth
Vireo Growth has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?